|
AU664392B2
(en)
*
|
1991-10-18 |
1995-11-16 |
Monsanto Technology Llc |
Fungicides for the control of take-all disease of plants
|
|
SE9703407D0
(sv)
*
|
1997-09-19 |
1997-09-19 |
Astra Ab |
New use
|
|
SE9802073D0
(sv)
|
1998-06-11 |
1998-06-11 |
Astra Ab |
New use
|
|
GB9825554D0
(en)
*
|
1998-11-20 |
1999-01-13 |
Smithkline Beecham Spa |
Novel Compounds
|
|
US7037922B1
(en)
*
|
2000-03-10 |
2006-05-02 |
Neurogen Corporation |
Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
|
|
EP1165542B1
(en)
|
1999-03-29 |
2003-08-20 |
Neurogen Corporation |
4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
|
|
WO2000064877A1
(en)
*
|
1999-04-26 |
2000-11-02 |
Neurogen Corporation |
2-aminoquinolinecarboxamides: neurokinin receptor ligands
|
|
JP2004525184A
(ja)
*
|
2001-04-11 |
2004-08-19 |
グラクソスミスクライン・ソシエタ・ペル・アチオニ |
Ｎｋ−３およびｎｋ−２受容体アンタゴニストとしての３−置換キノリン−４−カルボキサミド誘導体
|
|
WO2002089802A2
(en)
*
|
2001-05-08 |
2002-11-14 |
Schering Corporation |
Use of neurokinin receptor antagonists to treat androgen-dependent diseases
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
ATE477268T1
(de)
|
2003-01-28 |
2010-08-15 |
Ironwood Pharmaceuticals Inc |
Zusammensetzungen zur behandlung von magen-darm- störungen
|
|
GB0303086D0
(en)
|
2003-02-11 |
2003-03-19 |
Merck Sharp & Dohme |
New compounds
|
|
GB0419192D0
(en)
|
2004-08-27 |
2004-09-29 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
WO2006052722A1
(en)
*
|
2004-11-09 |
2006-05-18 |
Smithkline Beecham Corporation |
Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof
|
|
GB0425077D0
(en)
*
|
2004-11-12 |
2004-12-15 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0515580D0
(en)
|
2005-07-29 |
2005-09-07 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
EP1915361A1
(en)
*
|
2005-08-11 |
2008-04-30 |
AstraZeneca AB |
Alkylpyridyl quinolines as nk3 receptor modulators
|
|
AR057130A1
(es)
|
2005-09-21 |
2007-11-14 |
Astrazeneca Ab |
Quinolinas de alquilsulfoxido y una composicion farmaceutica
|
|
TW201018662A
(en)
*
|
2005-12-12 |
2010-05-16 |
Astrazeneca Ab |
Alkylsulphonamide quinolines
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
JP5546451B2
(ja)
|
2007-06-04 |
2014-07-09 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
|
|
US20100120694A1
(en)
|
2008-06-04 |
2010-05-13 |
Synergy Pharmaceuticals, Inc. |
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
|
|
MX2010003440A
(es)
*
|
2007-09-28 |
2010-04-21 |
Glaxosmithkline Llc |
Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo.
|
|
JP2010540553A
(ja)
*
|
2007-09-28 |
2010-12-24 |
グラクソスミスクライン エルエルシー |
グリコーゲンホスホリラーゼ阻害剤化合物及びその医薬組成物
|
|
EP3241839B1
(en)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
|
WO2018129556A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
JP5502106B2
(ja)
|
2008-12-31 |
2014-05-28 |
アーデリクス，インコーポレーテッド |
体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるｎｈｅ媒介性アンチポートを阻害するための組成物および方法
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US10376481B2
(en)
|
2012-08-21 |
2019-08-13 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
KR102138390B1
(ko)
|
2012-08-21 |
2020-07-27 |
알데릭스, 인코포레이티드 |
체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료에서 ｎｈｅ-매개된 역수송 저해를 위한 화합물 및 방법
|
|
HK1220696A1
(zh)
|
2013-03-15 |
2017-05-12 |
Bausch Health Ireland Limited |
鸟苷酸环化酶激动剂及其用途
|
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
|
KR102287207B1
(ko)
|
2013-04-12 |
2021-08-09 |
알데릭스, 인코포레이티드 |
Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법
|
|
AU2014255512A1
(en)
|
2013-04-19 |
2015-11-12 |
Astrazeneca Ab |
A NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
|
|
EP4424697A3
(en)
|
2013-06-05 |
2024-12-25 |
Bausch Health Ireland Limited |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
|
WO2017072629A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical combination of nk3 receptor antagonist and biguanides
|
|
CA3049679A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Inhibitors of nhe-mediated antiport
|
|
UA126283C2
(uk)
|
2017-01-09 |
2022-09-14 |
Арделікс, Інк. |
Сполуки, придатні для лікування розладів шлунково-кишкового тракту
|